BLACKSBURG, Va., Feb. 03, 2021 (GLOBE NEWSWIRE) –Landos Biopharma, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced the pricing of its initial public offering of 6,250,000 shares of common stock at the public offering price of $16.00 per share, for total gross proceeds of $100 million, before deducting underwriting discounts and commissions and offering expenses payable by Landos Biopharma. All of the shares of the common stock are being offered by Landos Biopharma.
{iframe}https://www.biospace.com/article/releases/landos-biopharma-announces-pricing-of-initial-public-offering/{/iframe}